Skip to main content
. Author manuscript; available in PMC: 2022 Oct 1.
Published in final edited form as: Int J Drug Policy. 2021 Apr 23;96:103238. doi: 10.1016/j.drugpo.2021.103238

Table 1.

Characteristics of participants

Participants 50
Age (average, range) 49 (31–66) Years
Ethnocultural identitya
First Nations 26 (52%)
Métis 3 (6%)
Black 1 (2%)
White 17 (34%)
Declined to answer 3 (6%)
HCV treatment status
Pre-treatmentb 20 (40%)
Peri-treatment 11 (22%)
Post-treatment 19 (38%)
HIV serostatus
Positive 24 (48%)
Negative 26 (52%)
Gender identity
Manc 26 (52%)
Womand 23 (46%)
Two-Spirite 1 (2%)
a

This category includes the ethnocultural identities described by participants themselves. The terms listed here are not intended to imply race-based categories; rather, these terms are intended to capture notions of self-identity and group identification.

b

This category includes one participant whose completed DAA treatment regimen did not result in cure, one participant who prematurely ceased DAA treatment due to adverse side effects, and one participant who re-acquired HCV after being cured with Interferon-based therapies several years prior. All of these participants expressed intent to (re)access DAA treatment.

c

All men who participated in this study identified as cisgender.

d

One woman who participated in this study identified as transgender, whereas the remaining women identified as cisgender.

e

“Two-Spirit” is an umbrella term intended to encapsulate a range of Indigenous gender diverse identities and non-normative sexual orientations (Carrier, Dame, & Lane, 2020). There is no singular definition of this term, as its use varies across and within Indigenous Peoples and communities.